

"T'EMPUS

Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2

August 1, 2024

New RNA-based algorithm is now available with the xR assay

CHICAGO--(BUSINESS WIRE)--Aug. 1, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using algorithms to surface patients who are more likely to test positive for actionable biomarkers, and who should receive confirmatory testing in accordance with clinical guidelines. This program is part of the larger [Tempus Next](#) platform, which is designed to identify care gaps and equip clinicians with actionable insights at the point of care. The new Next program is now available and initially focused on the identification of care gaps associated with the human epidermal growth factor receptor 2 (HER2) testing recommended under clinical guidelines for patients with select metastatic cancers.

As part of the initial launch, Tempus has built an algorithm that runs as part of [xR](#), the company's RNA sequencing assay, to help surface patients who are particularly likely to benefit from on-guideline immunohistochemistry (IHC) testing. The algorithm, which is run as part of Tempus' xR CAP/CLIA Laboratory Developed Test, uses RNA data to predict IHC/ISH positivity in a tumor sample. Tempus is initially deploying the program at a set of pilot sites. Tempus will notify physicians of patients who are identified by the algorithm as more likely to be HER2 positive, so that they can consider ordering confirmatory IHC testing from their laboratory of choice. The development of this program was funded by Tempus and one or more life sciences company sponsors.

"This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep connectivity with providers, comprehensive testing portfolio, and AI-enabled data analytics to deliver a tool that physicians can use in real-time to provide patients with the most up-to-date, guideline-directed care," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Next demonstrates how the practical application of AI can have a positive impact on everyday clinical care by meeting the needs of patients as treatment choices become increasingly complex."

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of Next and the indicated use of the product. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: changing Medicare rates; the intended use of Tempus' products and services; Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Final Prospectus filed with the Securities and Exchange Commission ("SEC") on June 17, 2024, pursuant to Rule 424(b)(4) under the Securities Act, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240801306537/en/): <https://www.businesswire.com/news/home/20240801306537/en/>

Erin Carron
erin.carron@tempus.com

Source: Tempus AI, Inc.